Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease.

J Intern Med. July 2017;282(1):46-63.

B Bonaz¹, V Sinniger², S Pellissier³

¹ University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.; ² University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.; ³ University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.

Abstract

Inflammatory bowel disease (IBD), that is Crohn's disease (CD) and ulcerative colitis, affects about 1.5 million persons in the USA and 2.2 million in Europe. The pathophysiology of IBD involves immunological, genetic and environmental factors. The treatment is medico-surgical but suspensive. Anti-TNFα agents have revolutionized the treatment of IBD but have side effects. In addition, a non-negligible percentage of patients with IBD stop or take episodically their treatment. Consequently, a nondrug therapy targeting TNFα through a physiological pathway, devoid of major side effects and with a good cost-effectiveness ratio, would be of interest. The vagus nerve has dual anti-inflammatory properties through its afferent (i.e. hypothalamic-pituitary-adrenal axis) and efferent (i.e. the anti-TNFα effect of the cholinergic anti-inflammatory pathway) fibres. We have shown that there is an inverse relationship between vagal tone and plasma TNFα level in patients with CD, and have reported, for the first time, that chronic vagus nerve stimulation has anti-inflammatory properties in a rat model of colitis and in a pilot study performed in seven patients with moderate CD. Two of these patients failed to improve after 3 months of vagus nerve stimulation but five were in deep remission (clinical, biological and endoscopic) at 6 months of follow-up and vagal tone was restored. No major side effects were observed. Thus, vagus nerve stimulation provides a new therapeutic option in the treatment of CD.

Article Tools:

Medline

Email to me

Databanks:

GENBANK/NCT01569503
GENBANK/NCT02311660

Archives Highlights:

Development of a dog owner caregiving style scale (Lincoln Owner Caregiving Questionnaire, LOCQ) and its relationship with behaviour problems in dogs
Compared to owners of dogs without behaviour problems, owners with high scores for the Disorganised caregiving style predicted dogs with separation related problems or with more than one behaviour problem, owners with high Avoidant caregiving style scores predicted dogs with Fear, and owners with high scores for both Disorganised and Avoidant caregiving styles predicted dogs with Aggressivity problems.

Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.

Performing an Avian Physical Examination in Practice
As with mammalian physical examinations, it is important to develop a consistent order for the avian examination to thoroughly evaluate each body system. Some components of the physical examination differ between avian species. For example, cloacal palpation is performed in chickens, but not in parrots.

The Most Common Environmental Risk Factors for Equine Asthma-A Narrative Review.
The symptoms of equine asthma are typical of respiratory inflammations, and they include coughing, nasal discharge, and breathing difficulty even at rest in horses with severe asthma. BALF and tracheal wash analyses are the most popular methods of diagnosing equine asthma. Inadequate housing conditions undoubtedly increase the risk of asthma.

Adjuvant Chemotherapy Is Associated With Prolonged Survival Time in Small-Breed Dogs Undergoing Amputation for Appendicular Osteosarcoma.
The median time to distant progression for all dogs was 265 days, with no significant difference between treatment groups. The median overall survival for all dogs was 270 days, and it was significantly different between amputated dogs (150 days) and those also receiving adjuvant chemotherapy (353 days). In our cohort, osteosarcoma in small breeds behaved as aggressive as in large breeds.